In the past week, LAB stock has gone up by 6.78%, with a monthly decline of -5.50% and a quarterly plunge of -13.30%. The volatility ratio for the week is 4.95%, and the volatility levels for the last 30 days are 5.23% for Standard BioTools Inc. The simple moving average for the past 20 days is 0.43% for LAB’s stock, with a -15.75% simple moving average for the past 200 days.
Is It Worth Investing in Standard BioTools Inc (NASDAQ: LAB) Right Now?
Additionally, the 36-month beta value for LAB is 1.57. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for LAB is 359.12M and currently, short sellers hold a 5.93% ratio of that float. The average trading volume of LAB on October 17, 2024 was 2.18M shares.
LAB) stock’s latest price update
Standard BioTools Inc (NASDAQ: LAB) has experienced a decline in its stock price by 0.00 compared to its previous closing price of 1.89. However, the company has seen a gain of 6.78% in its stock price over the last five trading days. globenewswire.com reported 2024-10-16 that SOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) — Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report third quarter 2024 financial results on Wednesday, October 30, 2024, after the close of the market.
Analysts’ Opinion of LAB
Many brokerage firms have already submitted their reports for LAB stocks, with TD Cowen repeating the rating for LAB by listing it as a “Buy.” The predicted price for LAB in the upcoming period, according to TD Cowen is $3.50 based on the research report published on April 16, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see LAB reach a price target of $3.25. The rating they have provided for LAB stocks is “Buy” according to the report published on April 04th, 2024.
KeyBanc Capital Markets gave a rating of “Overweight” to LAB, setting the target price at $4 in the report published on July 12th of the previous year.
LAB Trading at -0.82% from the 50-Day Moving Average
After a stumble in the market that brought LAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.83% of loss for the given period.
Volatility was left at 5.23%, however, over the last 30 days, the volatility rate increased by 4.95%, as shares sank -6.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +23.53% upper at present.
During the last 5 trading sessions, LAB rose by +6.78%, which changed the moving average for the period of 200-days by -14.48% in comparison to the 20-day moving average, which settled at $1.8820. In addition, Standard BioTools Inc saw -14.48% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LAB starting from Taich Adam, who proposed sale 45,851 shares at the price of $2.00 back on Sep 09 ’24. After this action, Taich Adam now owns shares of Standard BioTools Inc, valued at $91,725 using the latest closing price.
Casdin Partners Master Fund, L, the Director of Standard BioTools Inc, purchase 250,000 shares at $2.19 during a trade that took place back on Aug 27 ’24, which means that Casdin Partners Master Fund, L is holding 54,025,821 shares at $546,750 based on the most recent closing price.
Stock Fundamentals for LAB
Current profitability levels for the company are sitting at:
- -0.86 for the present operating margin
- 0.47 for the gross margin
The net margin for Standard BioTools Inc stands at -0.87. The total capital return value is set at -0.2. Equity return is now at value -59.79, with -22.29 for asset returns.
Based on Standard BioTools Inc (LAB), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -2.08. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -50.32.
Currently, EBITDA for the company is -47.86 million with net debt to EBITDA at 1.82. When we switch over and look at the enterprise to sales, we see a ratio of 3.83. The receivables turnover for the company is 4.2for trailing twelve months and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.88.
Conclusion
In conclusion, Standard BioTools Inc (LAB) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
